ArticlePLoS pathogens2018
A20 upregulation during treated HIV disease is associated with intestinal epithelial cell recovery and function.
Registry-linked trialOpen access · goldAbstract read
In one paragraph
Article in PLoS pathogens, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00594880 (Antiviral Activity of Peg-IFN-Alpha-2A in Chronic HIV-1 Infection), which is not on this map. Cited by 9 papers.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Antiviral Activity of Peg-IFN-Alpha-2A in Chronic HIV-1 Infection
Who cites it
9 citing papers in PubMed, 14 citations in OpenAlex.
- The Dual Role of A20 (TNFAIP3) in Viral Infection: A Context-Dependent Regulator of Immunity and Pathogenesis.Viruses · 2025Review
- Dynamic modulation of the non-canonical NF-κB signaling pathway for HIV shock and kill.Frontiers in cellular and infection microbiology · 2024Review
- Article
- The human microbiome and gut-liver axis in people living with HIV.Current HIV/AIDS reports · 2023Review
- Microbial signals, MyD88, and lymphotoxin drive TNF-independent intestinal epithelial tissue damage.The Journal of clinical investigation · 2022Article
- IL-17A reprograms intestinal epithelial cells to facilitate HIV-1 replication and outgrowth in CD4+ T cells.iScience · 2021Article
- A20 Restricts Inflammatory Response and Desensitizes Gingival Keratinocytes to Apoptosis.Frontiers in immunology · 2020Article
- HIV and the Gut Microbiota: Composition, Consequences, and Avenues for Amelioration.Current HIV/AIDS reports · 2019Review
- Deubiquitinating Enzymes and Bone Remodeling.Stem cells international · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Avantika S ChitreDivision of Experimental Medicine, University of California, San Francisco, San Francisco, CA, United States of America.
Michael G KattahDivision of Gastroenterology, University of California, San Francisco, San Francisco, CA, United States of America.ORCID 0000-0002-6067-6585
Yenny Y RosliDivision of Gastroenterology, University of California, San Francisco, San Francisco, CA, United States of America.
Montha PaoDivision of HIV/AIDS, University of California, San Francisco, San Francisco, CA, United States of America.
Monika DeswalDivision of HIV/AIDS, University of California, San Francisco, San Francisco, CA, United States of America.
Steven G DeeksDivision of HIV/AIDS, University of California, San Francisco, San Francisco, CA, United States of America.ORCID 0000-0001-6371-747X
Peter W HuntDivision of Experimental Medicine, University of California, San Francisco, San Francisco, CA, United States of America.
Mohamed Abdel-MohsenThe Wistar Institute, Philadelphia, PA, United States of America.
Luis J MontanerThe Wistar Institute, Philadelphia, PA, United States of America.ORCID 0000-0001-5799-6759
Charles C KimDivision of Experimental Medicine, University of California, San Francisco, San Francisco, CA, United States of America.
Averil MaDivision of Gastroenterology, University of California, San Francisco, San Francisco, CA, United States of America.
Ma SomsoukDivision of Gastroenterology, University of California, San Francisco, San Francisco, CA, United States of America.
Joseph M McCuneDivision of Experimental Medicine, University of California, San Francisco, San Francisco, CA, United States of America.ORCID 0000-0002-9388-070X
University of California, San Francisco · USThe Wistar Institute · US
Funding
UCSF CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024131 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSTON, S. CLAIBORNE · 2006 to 2011
$111.2MUnsolicited R24 for the CFAR-Network of Integrated Clinical Sciences, CNICSR24AI067039 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Michael S. Saag · 2006 to 2026
$99.4MVirology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALLORY O JOHNSON · 1988 to 2026
$93.6MVirus & Reservoirs CoreP30AI045008 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI DAVID S METZGER · 1999 to 2026
$78.6MViral reservoirs and sanctuaries in HAART - treated patients: role and mechanismsU19AI096109 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SCHACKER, TIMOTHY W · 2011 to 2015
$29.5MFirst-in-human study of two anti-SARS CoV-2 antibodies in health volunteersUM1AI126620 · NIAID · WISTAR INSTITUTE · PI MONTANER, LUIS J, RILEY, JAMES L. · 2016 to 2021
$24.5MTRAINING PROGRAM IN DISGESTIVE DISEASES AND NUTRITIONT32DK007007 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AVERIL I MA · 1986 to 2026
$6.4MPREDOCTORAL TRAINING IN BIOMEDICAL SCIENCEST32GM008568 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ANSEL, KARL MARK · 1995 to 2019
$6.3MRole of Intestinal Barrier Integrity in Modulating the Host Glycome During COVID-19R01DK123733 · NIDDK · WISTAR INSTITUTE · PI ABDEL MOHSEN, MOHAMED, KESHAVARZIAN, ALI · 2020 to 2024
$4.5MA20 Mediated Regulation of Colitis and SpondyloarthritisR01DK095693 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MA, AVERIL I · 2012 to 2021
$3.1MSialic Acid Modulation of HIV-associated Chronic InflammagingR01AG062383 · NIA · WISTAR INSTITUTE · PI ABDEL MOHSEN, MOHAMED · 2019 to 2023
$3.0MAntiviral activity of Peg-IFN alpha in chronic HIV-1U01AI065279 · NIAID · WISTAR INSTITUTE · PI MONTANER, LUIS J · 2005 to 2009
$2.8MNCRR NIH HHS UL1 RR024131NIAID NIH HHS P30 AI027763NIAID NIH HHS P30 AI045008NIAID NIH HHS R21 AI129636NIAID NIH HHS R21 AI143385NIAID NIH HHS R24 AI067039NIAID NIH HHS U01 AI065279NIAID NIH HHS U19 AI096109NIAID NIH HHS UM1 AI126620NIDDK NIH HHS R01 DK095693NIDDK NIH HHS T32 DK007007NIGMS NIH HHS T32 GM008568NIH HHS DK095693NIH HHS P30 A1027763NIH HHS R21 AI129636NIH HHS U01 AI065279NIH HHS U19 AI96109NIH HHS UM1 AI126620
Abstract
trial registrationClinicalTrials.gov Clinical Trial NCT00594880.
Indexed as
Antiretroviral Therapy, Highly ActiveAdultAnimalsEpithelial CellsFemaleHIV-1HIV InfectionsHumansIntestinal MucosaIntestinesMaleMiceMiddle AgedTumor Necrosis Factor alpha-Induced Protein 3Viral LoadTNFAIP3 protein, humanTumor Necrosis Factor alpha-Induced Protein 3
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT00594880ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.